Reports Q2 revenue $589,897 vs. $726,404 last year. “We continue to set a strong foundation that we believe positions us for success as we advance our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy across various oncology indications where there remains significant unmet need. We continue to work with our partners and believe the data and information will be invaluable as we look to realize the full potential of our DNase platform technology. Looking ahead, we remain focused on building momentum across all fronts and driving development toward an IND and Phase 1 clinical trial,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic (XBIO).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XBIO:
- Xenetic Biosciences Reports Improved Financial Performance
- Is XBIO a Buy, Before Earnings?
- Xenetic says PeriNess enters clinical study agreement for DNase Platform
- Xenetic expands collaboration with The Scripps Research Institute
- Xenetic says PeriNess reports Bnei Zion Medical Center commences patient dosing